TSRL Inc

TSRL, Inc. is a long-established, science-first preclinical CRO that offers a full suite of early development services including formulation, bioanalysis, PK/ADME, and toxicology. The company differentiates itself by combining these services with strategic consulting and proprietary drug delivery technology development, aiming to de-risk programs and guide clients toward licensing or business formation. With a 7,200 sq. ft. facility and a track record spanning nearly four decades, TSRL serves a broad client base while also advancing its own technology platforms through grant funding, such as a recent $2.2 million NIH SBIR grant for a microneedle patch for overactive bladder.

Integrated preclinical CRO services (formulation, bioanalysis, PK/ADME, tox) and proprietary Microarray Patch (MAP) drug delivery technology for non-invasive, self-administered systemic delivery.

TSRL competes in a fragmented preclinical CRO market against thousands of other service providers, ranging from large public CROs (e.g., Charles River, Labcorp) to small specialty labs. Its differentiation is based on scientific depth, integrated service offering, and strategic consulting. In drug delivery, it competes with specialized drug delivery companies and large pharma's internal development teams.